Stock Movers: Oracle's Cloud Sales Disappoint, Eli Lilly's Obesity Drug Shines, Gemini Rallies

Oracle's Cloud Sales Underperform

• 📉 Oracle shares dropped significantly due to AI data center spending outpacing cloud revenue realization.
• ⚠️ Despite a 34% increase in cloud sales to $7.98 billion and a 68% rise in infrastructure business to $4.08 billion, both fell short of analyst estimates.
• 💰 The market is concerned about the return on Oracle's substantial cloud investment, especially given its nearly $100 billion in debt.
• 🌐 This downturn impacted other tech stocks, with Nvidia, Coreweave, Nas, and Soft Bank also experiencing declines.

Eli Lilly's Obesity Drug Breakthrough

• 🚀 Eli Lilly & Co. shares surged following positive phase three trial results for their new obesity shot, retatrutide.
• 🎯 Patients on the highest dose lost nearly 23% of their body weight over 68 weeks, exceeding expectations and potentially making it the most potent weight loss medicine yet.
• 📈 Competitor Novo Nordisk shares also saw gains, indicating strong market confidence in the obesity drug sector.

Gemini Space Station's Regulatory Win

• 📈 Gemini Space Station Inc. shares rallied after the Commodity Futures Trading Commission (CFTC) approved its application for a derivatives exchange.
• 💡 This approval allows Gemini to enter the growing prediction markets field, enabling US customers to trade event contracts.
• 🔮 The company, co-founded by Tyler and Cameron Winklevoss, plans to offer prediction markets on economic, financial, political, and sports forecasts.